A new bioassay for the immunocytokine L19-IL2 for simultaneous analysis of both functional moieties

Journal of Pharmaceutical and Biomedical Analysis

Volumn 54, Issue 1, 2011, Pages 81-86

  Winter, Jonas ^a   Barbin, Karin ^a   Bacci, Camilla ^b   Bunte, Thomas ^a  

^a BAYER PHARMA AG   (Germany)

^b Philogen SpA   (Italy)

Author keywords

Assay validation; Bioassay; IL2; Immunocytokine; L19 IL2; Potency assay

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNOCYTOKINE L19 IL2; INTERLEUKIN 12; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOASSAY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG POTENCY; FREEZE THAWING; LIGAND BINDING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS;

ANIMALS; ANTIBODIES, MONOCLONAL; BIOLOGICAL ASSAY; CALIBRATION; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INTERLEUKIN-2; LIGANDS; MICE; PROTEIN BINDING; RECOMBINANT FUSION PROTEINS; REPRODUCIBILITY OF RESULTS; SINGLE-CHAIN ANTIBODIES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 77957019913     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2010.08.014     Document Type: Article

References (36)

1. Kohler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975, 256:495-497.
2. Reichert J.M., Valge-Archer V.E. Development trends for monoclonal antibody cancer therapeutics. Nat. Rev. Drug Discov. 2007, 6:349-356.
3. Reichert J.M., Wenger J.B. Development trends for new cancer therapeutics and vaccines. Drug Discov. Today 2008, 13:30-37.
4. Scallon B.J., Snyder L.A., Anderson G.M., Chen Q., Yan L., Weiner L.M., Nakada M.T. A review of antibody therapeutics and antibody-related technologies for oncology. J. Immunother. 2006, 29:351-364.
5. Ortiz-Sanchez E., Helguera G., Daniels T.R., Penichet M.L. Antibody-cytokine fusion proteins: applications in cancer therapy. Expert Opin. Biol. Ther. 2008, 8:609-632.
6. Dreier T., Lode H.N., Xiang R., Dolman C.S., Reisfeld R.A., Kang A.S. Recombinant immunocytokines targeting the mouse transferrin receptor: construction and biological activities. Bioconjug. Chem. 1998, 9:482-489.
7. Davis C., Gillies S. Immunocytokines: amplification of anti-cancer immunity. Cancer Immunol. Immunother. 2003, 52:297-308.
8. Tarli L., Balza E., Viti F., Borsi L., Castellani P., Berndorff D., Dinkelborg L., Neri D., Zardi L. A high-affinity human antibody that targets tumoral blood vessels. Blood 1999, 94:192-198.
9. Zardi L., Carnemolla B., Siri A., Petersen T.E., Paolella G., Sebastio G., Baralle F.E. Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon. EMBO J. 1987, 6:2337-2342.
10. Carnemolla B., Borsi L., Balza E., Castellani P., Meazza R., Berndt A., Ferrini S., Kosmehl H., Neri D., Zardi L. Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. Blood 2002, 99:1659-1665.
11. Wagner K., Schulz P., Scholz A., Wiedenmann B., Menrad A. The targeted immunocytokine L19-IL2 efficiently inhibits the growth of orthotopic pancreatic cancer. Clin. Cancer Res. 2008, 14:4951-4960.
12. John R.F. The functions of cytokines and their uses in toxicology. Int. J. Exp. Pathol. 2001, 82:171-192.
13. Mosmann T.R., Cherwinski H., Bond M.W., Giedlin M.A., Coffman R.L. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol. 1986, 136:2348-2357.
14. Hori T., Uchiyama T., Tsudo M., Umadome H., Ohno H., Fukuhara S., Kita K., Uchino H. Establishment of an interleukin 2-dependent human T cell line from a patient with T cell chronic lymphocytic leukemia who is not infected with human T cell leukemia/lymphoma virus. Blood 1987, 70:1069-1072.
15. Tada H., Shiho O., Kuroshima K., Koyama M., Tsukamoto K. An improved colorimetric assay for interleukin 2. J. Immunol. Methods 1986, 93:157-165.
16. Hammerling U., Henningsson A.C., Sjödin L. Development and validation of a bioassay for interleukin-2. J. Pharm. Biomed. Anal. 1992, 10:547-553.
17. Kwack K., Lynch R.G. A new non-radioactive method for IL-2 bioassay. Mol. Cells 2000, 10:575-578.
18. Gillis S., Ferm M.M., Ou W., Smith K.A. T cell growth factor: parameters of production and a quantitative microassay for activity. J. Immunol. 1978, 120:2027-2032.
19. El Emir E., Dearling J.L.J., Huhalov A., Robson M.P., Boxer G., Neri D., van Dongen G.A.M.S., Trachsel E., Begent R.H.J., Pedley R.B. Characterisation and radioimmunotherapy of L19-SIP, an anti-angiogenic antibody against the extra domain B of fibronectin, in colorectal tumour models. Br. J. Cancer 2007, 96:1862-1870.
20. Laura B., Enrica B., Marco B., Patrizia C., Barbara C., Attila B., Alessandra L., Jorge S., Oscar B., Dario N., Luciano Z. Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int. J. Cancer 2002, 102:75-85.
21. Berndorff D., Borkowski S., Moosmayer D., Viti F., Muller-Tiemann B., Sieger S., Friebe M., Hilger C.S., Zardi L., Neri D., Dinkelborg L.M. Imaging of tumor angiogenesis using 99mTc-labeled human recombinant anti-ED-B fibronectin antibody fragments. J. Nucl. Med. 2006, 47:1707-1716.
22. Kelley M., DeSilva B. Key elements of bioanalytical method validation for macromolecules. AAPS J. 2007, 9:E156-E163.
23. Findlay J.W.A., Smith W.C., Lee J.W., Nordblom G.D., Das I., DeSilva B.S., Khan M.N., Bowsher R.R. Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective. J. Pharm. Biomed. Anal. 2000, 21:1249-1273.
24. Miller K.J., Bowsher R.R., Celniker A., Gibbons J., Gupta S., Lee J.W., Swanson S.J., Smith W.C., Weiner R.S., Crommelin D.J.A., Das I., DeSilva B.S., Dillard R.F., Geier M., Gunn H., Khan M.N., Knuth D.W., Kunitani M., Nordblom G.D., Paulussen R.J.A., Sailstad J.M., Tacey R.L., Watson A. Workshop on bioanalytical methods validation for macromolecules: summary report. Pharm. Res. 2001, 18:1373-1383.
25. Smith W.C., Sittampalam G.S. Conceptual and statistical issues in the validation of analytic dilution assays for pharmaceutical applications. J. Biopharm. Stat. 1998, 8:509-532.
26. Hartmann C., Smeyers-Verbeke J., Massart D.L., McDowall R.D. Validation of bioanalytical chromatographic methods. J. Pharm. Biomed. Anal. 1998, 17:193-218.
27. Findlay J.W., Dillard R.F. Appropriate calibration curve fitting in ligand binding assays. AAPS J. 2007, 9:E260-E267.
28. Shah V., Midha K., Findlay J., Hill H., Hulse J., McGilveray I., McKay G., Miller K., Patnaik R., Powell M., Tonelli A., Viswanathan C.T., Yacobi A. Bioanalytical method validation-a revisit with a decade of progress. Pharm. Res. 2000, 17:1551-1557.
29. Smolec J., DeSilva B., Smith W., Weiner R., Kelly M., Lee B., Khan M., Tacey R., Hill H., Celniker A., Shah V., Bowsher R., Mire-Sluis A., Findlay J.W.A., Saltarelli M., Quarmby V., Lansky D., Dillard R., Ullmann M., Keller S., Karnes H.T. Bioanalytical method validation for macromolecules in support of pharmacokinetic studies. Pharm. Res. 2005, 22:1425-1431.
30. Viswanathan C., Bansal S., Booth B., DeStefano A., Rose M., Sailstad J., Shah V., Skelly J., Swann P., Weiner R. Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. Pharm. Res. 2007, 24:1962-1973.
31. Food and Drug Administration Guidance for Industry: Bioanalytical Method Validation 2001, US Department of Health and Human Services, FDA, Center for Drug Evaluation and Research, Rockville, MD.
32. DeSilva B., Smith W., Weiner R., Kelley M., Smolec J., Lee B., Khan M., Tacey R., Hill H., Celniker A. Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules. Pharm. Res. 2003, 20:1885-1900.
33. Das R., Robinson J. Assessing nonparallelism in bioassays: a discussion for nonstatisticians. BioProcess. Int. 2008, 6:46-56.
34. Finney D.J. Bioassay and the practice of statistical inference. Int. Stat. Rev. 1979, 47:1-12.
35. Wood E.C. The theory of certain analytical procedures, with particular reference to micro-biological assays. Analyst 1949, 71:1-14.
36. Hauck W.W, Capen R.C., Callahan J.D., De Muth J.E., Hsu H., Lansky D., Sajjadi N.C., Seaver S.S., Singer R.R., Weisman D. Assessing parallelism prior to determining relative potency. PDA J. Pharm. Sci. Technol. 2005, 59:127-137.